THE ROLE OF CATESTATIN AND RELAXIN-2 IN THE DIAGNOSIS OF PRIMARY HYPERTENSION AND TYPE 2 DIABETES: THE RESULTS OF 12-MONTH FOLLOW-UP
DOI:
https://doi.org/10.32782/health-2023.4.8Keywords:
primary hypertension, type 2 diabetes mellitus, catestatin, relaxin-2, cardiovascular complicationsAbstract
The aim is to investigate the frequency of adverse cardiovascular events in patients with primary hypertension (PH) depending on plasma catestatin (CST) and relaxin-2 (RLN-2) levels during 12-months follow-up. Materials and methods. 136 study participants were involved in the study: 106 patients with PH and 30 healthy volunteers. Depending on the presence of concomitant type 2 diabetes (T2DM), patients with PH were divided into 2 groups: 1st group – 55 patients with PH and T2DM, 2nd group – 51 patients with PH without T2DM. All study subjects underwent a comprehensive clinical examination, laboratory and instrumental investigations at the screening visit with follow-up during 12 months regarding the development of endpoints: cardiac death, ischemic stroke, acute myocardial infarction, acute heart failure. Plasma CTS and RLN-2 concentrations were determined using enzyme-linked immunosorbent assay. Statistical data analysis was performed using the SPSS 25.0 statistical software. Results. Major adverse cardiovascular events were registered in patients with PH, while there were not detected any endpoint in the control group. A slightly higher frequency of endpoint development was observed in patients with PH and T2DM, but the difference was not statistically significant (p>0.05). There was established a significantly higher frequency of the development of endpoints in patients with CTS concentrations<5.44 ng/ml (p=0.01), while no differences were found regarding the development of cardiovascular complications depending on RLN-2 levels (p=0.37). Conclusions. PH leads to an increased risk of cardiac mortality and non-fatal serious cardiovascular complications. The established increased risk of adverse cardiovascular events in PH patients with lower concentrations of CTS indicates the relationship of CTS levels with the course of the disease and its potential in the diagnosis of PH.
References
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020. Vol. 396, № 10258. P. 1223–1249. DOI: https://doi.org/10.1016/S0140-6736(20)30752-2.
World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva, Switzerland : World Health Organization. 2021. P. 1–61. URL: https://iris.who.int/bitstream/handle/10665/344424/9789240033986-eng. pdf (дата звернення: 27.11.2023).
International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium : International Diabetes Federation. 2021. P. 1–135. URL: https://diabetesatlas.org/atlas/tenth-edition/ (дата звернення: 27.11.2023).
Zalewska E., Kmieć P., Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Frontiers in cardiovascular medicine. 2022. Vol. 9. Art. 909480. DOI: https://doi.org/10.3389/fcvm.2022.909480.
Панкова О.А. Потенціал катестатину у діагностиці серцево-судинних захворювань: сучасні дані та перспективи. Східноєвропейський журнал внутрішньої та сімейної медицини. 2022. № 2. С. 43–48. DOI: https://doi.org/10.15407/internalmed2022.02.043.
Aragón-Herrera A., Feijóo-Bandín S., Anido-Varela L., Moraña-Fernández S., Roselló-Lletí E., Portolés M., Tarazón E., Gualillo O., González-Juanatey J.R., Lago F. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases. Journal of personalized medicine. 2022. Vol. 12, № 7. Art. 1021. DOI: https://doi.org/10.3390/jpm12071021.
Панкова О.А. Релаксин-2 – перспективний біомаркер кардіометаболічних захворювань. Міжнародний медичний журнал. 2022. № 1(109). С. 11–16. DOI: https://doi.org/10.37436/2308-5274-2022-1-2w.
Pankova O., Korzh O. Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus. Heart and Vessels. 2023 Sep 27. DOI: https://doi.org/10.1007/s00380-023-02318-w.
Wołowiec Ł., Rogowicz D., Banach J., Gilewski W., Sinkiewicz W., Grześk G. Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up. Disease markers. 2020. Art. 8847211. DOI: https://doi.org/10.1155/2020/8847211.
Liu L., Ding W., Zhao F., Shi L., Pang Y., Tang C. Plasma levels and potential roles of catestatin in patients with coronary heart disease. Scandinavian cardiovascular journal. 2013. Vol. 47, № 4. P. 217–224. DOI: https://doi.org/10.3109/14017431.2013.794951.
Xu W., Yu H., Wu H., Li S., Chen B., Gao W. Plasma Catestatin in Patients with Acute Coronary Syndrome. Cardiology. 2017. Vol. 136, № 3. P. 164–169. DOI: https://doi.org/10.1159/000448987.
Xu W.X., Fan Y.Y., Song Y., Liu X., Liu H., Guo L.J. Prognostic differences of catestatin among young and elderly patients with acute myocardial infarction. World journal of emergency medicine. 2022. Vol. 13, № 3. P. 169–174. DOI: https://doi.org/10.5847/wjem.j.1920-8642.2022.055.
Zhu D., Xie H., Wang X., Liang Y., Yu H., Gao W. Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction. PLoS One. 2015. Vol. 10, № 4. Art. e0122993. DOI: https://doi.org/10.1371/journal.pone.0122993.
Zhu D., Xie H., Wang X., Liang Y., Yu H., Gao W. Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction. Scientific reports. 2017. Vol. 7. Art. 44168. DOI: https://doi.org/10.1038/srep44168.
Peng F., Chu S., Ding W., Liu L., Zhao J., Cui X., Li R., Wang J. The predictive value of plasma catestatin for allcause and cardiac deaths in chronic heart failure patients. Peptides. 2016. Vol. 86. P. 112–117. DOI: https://doi.org/10.1016/j.peptides.2016.10.007.
Sun H., Xian W., Geng L., Li E., Peng Z., Tian J. Increased plasma level of catestatin might be associated with poor prognosis in hemodialysis patients. International urology and nephrology. 2017. Vol. 49, № 6. P. 1063–1069. DOI: https://doi.org/10.1007/s11255-017-1528-8.
Fisher C., Berry C., Blue L., Morton J.J., McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003. Vol. 89, № 8. P. 879–881. DOI: https://doi.org/10.1136/heart.89.8.879.
Herrero-Puente P., Prieto-García B., García-García M., Llorens P., Martín-Sánchez F.J., Jacob J., Mebazaa A., Mueller C., Maisel A.S., Gil V., García-Hernandez P., Miró Ò. The relationship of circulating relaxin-2 concentrations with short-term prognosis in patients with acute heart failure: the RELAHF study. European journal of heart failure. 2017. Vol. 19, № 9. P. 1205–1209. DOI: https://doi.org/10.1002/ejhf.875.
Miró Ò., Herrero-Puente P., Prieto B., García-García M., García-Hernández P., Martín-Sánchez F.J., Jacob J., Ríos J., Romero R., Gil V., Gayat É., Llorens P., Mebazaa A. The subset of patients with acute heart failure able to secrete relaxin-2 at pregnancy concentrations could have a longer survival: a pilot study. Biomarkers. 2018. Vol. 23, № 6. P. 573–579. DOI: https://doi.org/10.1080/1354750X.2018.1463564.
Zhou H., Qu X., Gao Z., Zheng G., Lin J., Su L., Huang Z., Li H., Huang W. Relaxin Level in Patients With Atrial Fibrillation and Association with Heart Failure Occurrence: A STROBE Compliant Article. Medicine (Baltimore). 2016. Vol. 95, № 21. Art. e3664. DOI: https://doi.org/10.1097/MD.0000000000003664.
Qu X., Chen L., Sun L., Chen C., Gao Z., Huang W., Zhou H. Serum relaxin level predicts recurrence of atrial fibrillation after radiofrequency catheter ablation. Heart and Vessels. 2019. Vol. 34, № 9. P. 1543–1551. DOI: https://doi.org/10.1007/s00380-019-01386-1.
Binder C., Simon A., Binder L., Hagemann T., Schulz M., Emons G., Trümper L., Einspanier A. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast cancer research and treatment. 2004. Vol. 87, № 2. P. 157–166. DOI: https://doi.org/10.1023/B:BREA.0000041622.30169.16.
Xu Y., Yu Q., Liu Y. Serum relaxin-2 as a novel biomarker for prostate cancer. British journal of biomedical science. 2018. Vol. 75, № 3. P. 145–148. DOI: https://doi.org/10.1080/09674845.2018.1424499.
Ren P., Yu Z.T., Xiu L., Wang M., Liu H.M. Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma. World journal of gastroenterology. 2013. Vol. 19, № 15. P. 2412–2418. DOI: https://doi.org/10.3748/wjg.v19.i15.2412.
Pan H.Z., Dong A.B., Wang L., Tan S.S., Yang Q., Tong X.Y., Liang J., Wang J.R. Significance of relaxin-2 expression in hepatocellular carcinoma: relation with clinicopathological parameters. European Review for Medical and Pharmacological Sciences. 2013. Vol. 17, № 8. P. 1095–1101.
